Axis Shield

Axis Shield main website

Axis Shield
  • HOMOCYSTEINE
Skip to content
  • Main
  • About Us
  • Disease Areas
    • Rheumatoid Arthritis
    • Cardiovascular
    • Infectious Diseases
    • Sepsis
    • Vitamin B12 Deficiency
    • Diabetes
  • Products
    • Clinical Chemistry Anti-CCP
    • Active-B12
    • HbA1c
    • Heparin Binding Protein
    • Anti-CCP ELISA
    • Homocysteine EIA
    • Enzymatic Homocysteine
    • SyphScreen RPR
    • MICROSYPH TPHA
    • OEM
  • Contact Us
  • Technical Library
  • At Axis-Shield, innovation is fundamental to our business. There is an increasing need for new diagnostic tests in many disease areas.
  • We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence.
  • Identifying these diseases quickly and efficiently can be vital in maintaining a patient's quality of life.
  • New drug treatments are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.
  • At Axis-Shield, innovation is fundamental to our business. There is an increasing need for new diagnostic tests in many disease areas.
  • We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence.
  • Identifying these diseases quickly and efficiently can be vital in maintaining a patient's quality of life.
  • New drug treatments are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.

Major new publication on HBP

Our new sepsis marker HBP is the subject of an important new paper which supports its use in identifying patients who are at risk of developing severe sepsis.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603368/pdf/ccm-43-2378.pdf

For more information on HBP please visit www.heparinbindingprotein.com

This entry was posted in News on 4th November 2015 by Fiona Harris.

Post navigation

← MEDICA 2015 ISICEM 2016 →

Focus on Anti-CCP

anti-CCP Anti-CCP is the marker of choice for the aid in the diagnosis of Rheumatoid Arthritis. Our new Chemistry assay for Anti-CCP antibodies complements our proven ELISA assay.

Contact Us

Axis-Shield Diagnostics Ltd.
Luna Place
The Technology Park
Dundee DD2 1XA
Scotland

T: +44 (0)1382 422000
F: +44 (0)1382 422088

Registered in Scotland: 77359

Terms & Conditions
Privacy Policy

Axis Shield at a Glance

A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories.

Axis Shield